Furthermore, C-dots have been evaluated in patients with metastatic melanoma, brain tumors, and head and neck cancers (NCT01266096, NCT02106598, NCT03465618), and some versions such as 64Cu-NOTA-PSMA-PEG-Cy5.5-C dots have also entered trials for the identification of tumor cells during prostate cancer surgery (NCT04167969) [297]. The gene discussed is FOLH1; the disease is prostate carcinoma.